Tonix Pharmaceuticals publishes Phase 1 data for TNX-1500 anti-CD40L antibody

Tonix announced publication of Phase 1 clinical data for TNX-1500 in the Journal of Clinical Immunology, showing the drug was well-tolerated with favorable safety profile. A Phase 2 investigator-initiated kidney transplant study at Massachusetts General Hospital is expected to begin in H2 2026, potentially establishing TNX-1500 as first-in-class therapy for organ transplant rejection prevention.